Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 17/20 | 0.48 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.41 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17653263 | 0.93 | AAK1 (0.48) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL19253030 | 0.93 | AAK1 (0.48) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17783188 | 0.89 | AAK1 (0.49) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17783187 | 0.89 | AAK1 (0.49) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17663467 | 0.88 | AAK1 (0.48) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL19252991 | 0.88 | AAK1 (0.48) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17653282 | 0.87 | AAK1 (0.47) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17653278 | 0.87 | AAK1 (0.47) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL19253007 | 0.81 | AAK1 (0.57) | AAK1MAP1LC3BMAP1LC3ACTSLCTSB | |
| SCHEMBL17783160 | 0.80 | AAK1 (0.75) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | AAK1, ULK1, NCK1 | AAK1 1/4885MAP1LC3B 884/4885MAP1LC3A 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.